Eutilex said that it has patented EU101, an immunotherapy targeting 4-1BB, in Australia.
The patent registration comes after the company completed the U.S. patent registration in January. With the latest registration, the company has now registered patents for the substance in nine countries, including the U.S., Japan, Canada, and Singapore.
Eutilex is planning to conduct phase 1 clinical trials in Korea next year.
“The reason Eutilex’s substance is so competitive among existing antibody treatments is that the company has found the appropriate antigen binding site, which has a high anti-cancer effect and no hepatotoxicity,” a company official said. “This patent registration has secured the Australian patent right for EU101 antibody and antigen binding site until 2037.”
Eutilex Vice President Choi So-hee said, “The company is actively seeking to build a global patent portfolio and patent rights to gain a strong footing in transferring its technology to a multinational pharmaceutical firm later on.”
<© Korea Biomedical Review, All rights reserved.>